RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 123 filers reported holding RHYTHM PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 2.18 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $41,000 | -100.0% | 10 | -99.9% | 0.00% | -100.0% |
| Q1 2022 | $117,877,000 | +49.8% | 10,233 | +29.8% | 0.03% | +73.7% |
| Q4 2021 | $78,699,000 | -21.4% | 7,886 | +52.6% | 0.02% | -17.4% |
| Q2 2021 | $100,134,000 | -8.9% | 5,167 | 0.0% | 0.02% | -25.8% |
| Q1 2021 | $109,897,000 | -40.1% | 5,167 | -16.3% | 0.03% | -42.6% |
| Q4 2020 | $183,545,000 | +37.2% | 6,174 | 0.0% | 0.05% | +38.5% |
| Q3 2020 | $133,783,000 | +0.7% | 6,174 | +3.6% | 0.04% | +8.3% |
| Q2 2020 | $132,899,000 | +46.5% | 5,960 | 0.0% | 0.04% | +44.0% |
| Q1 2020 | $90,707,000 | – | 5,960 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 2,075,000 | $47,569,375 | 5.56% |
| NEA Management Company, LLC | 2,909,956 | $66,710,741 | 5.15% |
| Opaleye Management Inc. | 653,000 | $14,970,025 | 4.87% |
| Frazier Life Sciences Management, L.P. | 2,371,304 | $54,362,144 | 3.61% |
| VR Adviser, LLC | 1,090,000 | $24,988,250 | 2.63% |
| RA Capital Management | 5,676,067 | $130,123,836 | 2.56% |
| Samsara BioCapital, LLC | 345,293 | $7,915,842 | 2.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 260,537 | $5,972,811 | 1.81% |
| Logos Global Management LP | 400,000 | $9,170,000 | 1.22% |
| Cormorant Asset Management, LP | 850,000 | $19,486,250 | 1.14% |